First Tracks Biotherapeutics, Inc. - Ordinary Shares (TRAX)

First Tracks Biotherapeutics (NASDAQ:TRAX) reported top-line results from the first cohort of its Phase Ib study of ANB033 in celiac disease, saying the investigational CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge. The cohort enrolled 3